

Archives of Virology

Full-length genome sequence analysis of a Hungarian Porcine Reproductive and Respiratory Syndrome Virus isolated from severe respiratory disease --Manuscript Draft--

Manuscript Number:	ARVI-D-14-00275R1
Full Title:	Full-length genome sequence analysis of a Hungarian Porcine Reproductive and Respiratory Syndrome Virus isolated from severe respiratory disease
Article Type:	Brief Report
Corresponding Author:	adam balint National food Chain safety Office Veterinary Diagnostic Directorate Budapest, HUNGARY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	National food Chain safety Office Veterinary Diagnostic Directorate
Corresponding Author's Secondary Institution:	
First Author:	adam balint
First Author Secondary Information:	
Order of Authors:	adam balint Gyula Balka Péter Horváth Sándor Kecskeméti Ádám Dán Attila Farsang Levente Szeredi Krisztián Bányai Dániel Bartha Ferenc Olasz Sándor Belák Zoltán Zádori
Order of Authors Secondary Information:	
Abstract:	The authors report the isolation of a Type 1 PRRSV strain from a clinical outbreak of severe respiratory problems and high fever. Next generation sequencing was used to determine the complete genome sequence of the isolate (9625/2012). The virus belongs to a new branch within subtype 1, clade D, containing mostly Spanish sequences and shows highest similarity to PRRSV Olot/1991 and to the Amervac vaccine strain. SimPlot analysis performed with the available full-length genome sequences indicates no evidences of recombination. Mutation analysis of 9625/2012 and the most related strains revealed high proportion of amino acid substitutions in the putative neutralizing epitopes, suggesting an important role of the selective immune pressure in the evolution of PRRSV 9625/2012.
Response to Reviewers:	The manuscript by Balint et al reports the full genome sequence of an Hungarian isolate of Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and phylogenetic analyses. Full genome sequences of PRRSV and studies on genetic diversity of PRRSV have been already reported; however, there is scarce complete genome data available for Hungarian PRRSV isolates so the report does provide some information that could be of interest to those investigators working in the field and

overall to readers of Archives of Virology. However, the study is more appropriate for a short report. The article has been shortened to a brief report format, but the overall structure has not been changed, the methods are concise and reproducible, the result and discussion sections are only shortened slightly.

Specific comment are detail below:

1. Although the manuscript is well written, there are some inconsistencies in the abbreviations. For instance, page 3 line 36, it reads INF, the word should be spelled out completely the first time is used. It seems that the authors are refering to interferon and as such, this should be clear. If this is the case, the abbreviated form can be used in the discussion section, instead of the word "interferon." We have doublechecked the text for such inconsistencies, and the abbreviations are explained when necessary.
2. Phylogenetic trees should included an outgroup to obtain appropriate distances and to be more informative. We changed the phylogenetic tree by including acc. numbers, and marking our strain. Probably it was not highlighted enough but an outgroup (Type 2 reference strain VR2332) was already included in the original tree, and was also indicated in the text. We did not change that.
3. Some of the tables (primers, genbank accession etc) can be ommited. Genbank accession number information can be easily included in the phylogenetic tree. Genbank accession numbers were added to the phylogenetic tree, and contents of table 3 and 4 were added to the text. In our opinion the table descscbing the primers used for sequencing can not be omitted as it will be very confusing to list all the primer names, sequences and attachment sites in the text. Former Figure 1, showing SimPlot results has been omitted, as it shows no evidences of recombination, as it is basically a negative test, thus the results are described in the text.

The manuscript by Balint et al reports the full genome sequence of an Hungarian isolate of Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and phylogenetic analyses. Full genome sequences of PRRSV and studies on genetic diversity of PRRSV have been already reported; however, there is scarce complete genome data available for Hungarian PRRSV isolates so the report does provide some information that could be of interest to those investigators working in the field and overall to readers of Archives of Virology. However, the study is more appropriate for a short report. **The article has been shortened to a brief report format, but the overall structure has not been changed, the methods are concise and reproducible, the result and discussion sections are only shortened slightly.**

Specific comment are detail below:

1. Although the manuscript is well written, there are some inconsistencies in the abbreviations. For instance, page 3 line 36, it reads INF, the word should be spelled out completely the first time is used. It seems that the authors are referring to interferon and as such, this should be clear. If this is the case, the abbreviated form can be used in the discussion section, instead of the word "interferon." **We have doublechecked the text for such inconsistencies, and the abbreviations are explained when necessary.**
2. Phylogenetic trees should included an outgroup to obtain appropriate distances and to be more informative. **We changed the phylogenetic tree by including acc. numbers, and marking our strain. Probably it was not highlighted enough but an outgroup (Type 2 reference strain VR2332) was already included in the original tree, and was also indicated in the text. We did not change that.**
3. Some of the tables (primers, genbank accession etc) can be ommited. Genbank accession number information can be easily included in the phylogenetic tree. **Genbank accession numbers were added to the phylogenetic tree, and contents of table 3 and 4 were added to the text. In our opinion the table descscibing the primers used for sequencing can not be omitted as it will be very confusing to list all the primer names, sequences and attachment sites in the text. Former Figure 1, showing SimPlot results has been omitted, as it shows no evidences of recombination, as it is basically a negative test, thus the results are described in the text.**

**Full-length genome sequence analysis of a Hungarian Porcine Reproductive and
Respiratory Syndrome Virus isolated from severe respiratory disease**

Ádám Bálint*, Gyula Balka, Péter Horváth, Sándor Kecskeméti, Ádám Dán, Attila Farsang,
Levente Szeredi, Krisztián Bányai, Dániel Bartha, Ferenc Olasz, Sándor Belák, Zoltán Zádori

Á. Bálint, S. Kecskeméti, Á. Dán, L. Szeredi
National Food Chain Safety Office Veterinary Diagnostic Directorate, Tábornok u. 2, H-1149
Budapest, Hungary

Gy. Balka
Szent István University, Faculty of Veterinary Science, Department of Pathology, István u. 2,
H-1078, Budapest, Hungary

P. Horváth, K. Bányai, D. Bartha, F. Olasz, Z. Zádori
Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian
Academy of Sciences, Hungária krt. 21, H-1143 Budapest, Hungary

A. Farsang
National Food Chain Safety Office Directorate of Veterinary Medicinal Products, Szállás u. 8,
H-1107, Budapest, Hungary

S. Belák
Department of Virology, Immunobiology and Parasitology, National Veterinary Institute,
SVA, Ulls väg 2B, SE-751 89 Uppsala, Sweden

*Corresponding author:

Phone: +36 1 460 63 74

Fax: +36 1 252 51 77

e-mail: balintad@nebih.gov.hu

Keywords:

PRRSV, sequencing, complete genome, epitope

Abstract

1
2 The authors report the isolation of a Type 1 PRRSV strain from a clinical outbreak of severe
3 respiratory problems and high fever. Next generation sequencing was used to determine the
4 complete genome sequence of the isolate (9625/2012). The virus belongs to a new branch
5 within subtype 1, clade D and shows the highest similarity to PRRSV Olot/1991 and to the
6 Amervac vaccine strain. Mutation analysis of 9625/2012 indicates no evidences of
7 recombination and it revealed high proportion of amino acid substitutions in the putative
8 neutralizing epitopes, suggesting an important role of the selective immune pressure in the
9 evolution of PRRSV 9625/2012.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Porcine Reproductive and Respiratory Syndrome (PRRS) is characterized by reproductive and
2 respiratory symptoms, reductions in growth performance and increased mortality in young
3 pigs. The etiological agent, Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)
4 belongs to the Arterivirus genus within the *Arteriviridae* family [1], and its strains are divided
5 into two major genotypes. Type 1 viruses are related to the early European isolates while
6 Type 2 genotype viruses are related to the original North American strains. Recent data show
7 that significant genetic variability can occur not only between but also within genotypes [2].
8 Excessive variability among Type 1 strains led to the introduction of four distinct subtypes
9 [3].

10 The genetic variability may correspond to the wide range of symptoms extending from
11 lack of clinical signs to fatal disease. Highly virulent PRRSV strains of both genotypes have
12 been isolated from severe clinical cases from all over the world [4]. Type 1 subtype 3 strains
13 ‘Lena’ and ‘SU1-bel’ induced increased clinical pathological effects in challenge models [5,
14 6].

15 Multiple genomic regions are responsible for the immunological behaviour and the
16 virulence of the PRRSV and this fact underlines the significance of full-length genome
17 sequencing. Several studies have confirmed the role of non-structural proteins of PRRSV in
18 the modulation of host immune reactions mainly by blocking type I INF (interferon)
19 responses of the innate immunity [7, 8]. It was shown that GP5, encoded by ORF5, contains
20 B-cell neutralizing epitope, with the presence of multiple glycosylation sites and similarly to
21 other Arteriviruses, an immunodominant decoy epitope is located in its proximity [9, 10]. T-
22 cell epitopes have also been identified on both the GP5 and the N protein (encoded by ORF7)
23 by *in silico* prediction and *ex vivo* evaluation [11].

24 Severe respiratory disease with high fever was observed in a non-vaccinated,
25 originally PRRS-free fattening herd of 2500 animals (aged 4–5 months) in Eastern Hungary
26 during 2012. The symptoms were resistant to antibiotic treatment, and in prolonged cases,
27 posterior paresis and skin haemorrhages were observed. Despite the high (90%) morbidity,
28 mortality remained at low level (0.2%). Thorough diagnostic examinations detected the
29 presence of PRRSV in the clinical specimens originated from the infected herd.

30 The aim of the present study was to determine the full-length genome sequence of the
31 PRRSV strain isolated from the aforementioned outbreak and to make an attempt to identify
32 putative genetic markers contributing to the severe clinical disease, and to perform
33 epidemiological investigations to reveal the origin of the strain.

34 Detailed diagnostic examinations of five perished pigs originating from the infected
35 herds were performed, based on standard protocols of the National Food Chain Safety Office,
36 Veterinary Diagnostic Directorate, Budapest, Hungary. For PRRSV detection, a real time
37 PCR assay was executed as described earlier [12], whilst for sequencing of ORF5 and ORF7,
38 primer pairs described by Balka et al. [13] were applied.

39 Major respiratory viral and bacterial swine pathogens like classical and African swine
40 fever, SIV, ADV, PCV-2, *Actinobacillus pleuropneumoniae*, *Salmonella choleraesuis*,
41 *Streptococcus suis* were tested according to the current protocols of the World Organisation
42 for Animal Health [14]. *Mycoplasma hyopneumoniae* was tested by PCR, according to
43 Stemke et al. [15].

44 Culture of porcine alveolar macrophages (PAMs) was prepared according to the OIE
45 Manuals [14]. Lung tissue homogenates of PRRSV 9625/2012 were prepared with Tissue
46 Lyser (Qiagen, Hilden, Germany) in sterile phosphate-buffered saline (PBS) containing
47 antibiotics and antimycotics, and centrifuged at 5000 ×g for 10 min. Cell-free supernatants
48 were aliquoted and stored at –80°C for inoculation and RNA isolation. PAMs were inoculated
49 with 100 µl of supernatant and incubated for five days.

1 RNA was isolated with QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) and
2 cDNA was generated using Superscript III First-Strand Synthesis System for RT-PCR
3 (Invitrogen, Carlsbad, CA, USA) kit and a T₂₀ primer, according to the protocol of the
4 manufacturer.

5 The genome of PRRSV 9625/2012 was amplified in six overlapping parts, using The
6 Phusion II HotStart PCR kit (Thermo Scientific, Waltham, MA, USA), in 25 µl final volume
7 with 1 µl of cDNA template, in 1x GC buffer in the presence of 4% DMSO. Amplification
8 was performed using the following gradient PCR programme: 98°C 1', 35 × [98°C 20", 54-
9 72°C (gradient ramp: 2°C) 20", 72°C 5'], 72°C 5'. The primer pairs used for the amplification
10 of the different fragments are listed in Table 1. For determination of both ends of the genome,
11 the 5' RACE System for Rapid Amplification of cDNA Ends, version 2.0 (Invitrogen,
12 Carlsbad, CA, USA) as well as a forward ORF7 primer [13] and the T₂₀ primer were applied.
13

14 An equimolar mixture of the overlapping PRRSV PCR products was used as template
15 for next generation sequencing. Sequencing was carried out on a 316 Chip using the Ion
16 Torrent semiconductor sequencing equipment (Ion Personal Genome Machine® (PGMTM);
17 Life Technologies) according to the manufacturer's recommendation. Sequences were
18 assembled and aligned with the SeqMan Ngen software (Lasergene, Madison, WI, USA).
19

20 MEGA software v.5.1 [16] was used to align DNA and protein sequences and to build
21 a phylogenetic reconstruction. Neighbor-joining algorithm was implemented with the
22 Kimura-2 parameters model using a transition-to-transversion ratio of 2.0. The topology of
23 trees was confirmed by 1000 bootstrap replicates. The SimPlot programme [17] was applied
24 for visualizing similarity along the whole genome. Potential N-linked glycosylation sites
25 (score >0.5) were predicted by the NetNGlyc 1.0 Server [18].
26

27 The presence of PRRSV and *Mycoplasma hyopneumoniae* in the five investigated pigs
28 was confirmed by real-time PCR and conventional PCR, respectively. The absence of other
29 respiratory and generalized bacterial infection was diagnostically confirmed by bacterial
30 cultivation, serology, and PCR.
31

32 The full length sequence of PRRSV 9625/2012 was 15098 nt long (Genbank Acc. No:
33 KJ415276). At genome level, the overall nucleotide identity was 96%, 95%, 92% and 58%
34 with PRRSV strains Amervac MLV, Olot/1991, Lelystad (acc.: M96262) and the Type 2
35 prototype strain VR-2332 (acc.: U87392), respectively.
36

37 PRRSV 9625/2012 showed the closest similarity to the vaccine strain Amervac MLV
38 (613 nucleotide change with no deletion/insertion) raising the possibility of direct
39 descendancy between the two viruses, which could have been facilitated by viral transmission
40 after vaccination.
41

42 No signs of recombination with Amervac MLV or other PRRSV strains were observed
43 according to the SimPlot analysis (data not shown) indicating the lack of such an event in the
44 evolution of PRRSV 9625/2012. Throughout the whole genome the Amervac MLV and
45 Olot/91 strains exhibited the closest similarity, ranging between 86–99%, but never reached
46 100%. Nucleotide similarity fluctuated between 79–98% and 0–73% with PRRSV type 1
47 Lelystad and Type 2 VR-2332 reference strains, respectively.
48

49 The phylogenetic tree using ORF5 sequences from a selection of Type 1 strains and
50 VR-2332 as outgroup revealed that PRRSV 9625/2012 is a Type 1, subtype 1 virus within
51 Clade D, defined by Shi et al. 2010 [5]. The closest (96%) nucleotide identity was shared with
52 Spanish and other, MLV-like strains (Fig. 1) that have already been present in Hungary for a
53 decade [13], but our strain seems to represent a previously unknown evolutionary branch
54 within this clade.
55

56 The analysis of the putative amino acid (aa) sequences of the aforementioned three
57 strains revealed that the most aa variations are found in Nsp1 (93% identity, 96–97%
58
59
60
61
62
63
64
65

1 similarity) and Nsp2 (93% identity, 94–95% similarity). The structural proteins of PRRSV
2 9625/2012 showed 94–98% identity with Amervac MLV and Olot/1991.

3 We compared the antigenic regions (ARs) within GP2, GP3, GP4 and GP5 proteins of
4 PRRSV 9625/2012 with Amervac MLV and Olot/1991, since these proteins are the main
5 targets for neutralizing antibodies.

6 In the two neutralizing epitopes AR II and AR IV of GP2 [9, 19], one-one aa
7 substitutions were found, respectively (Fig. 2a). Additionally, two aa substitutions were also
8 detected right upstream of AR II. In the non-neutralizing ARs I, III and V, two, one and zero
9 aa substitutions were observed, respectively. In the non-antigenic part of the protein, only
10 three aa differences were found (Fig 2a).

11 In the two neutralizing epitopes AR I and AR VIII [19, 20] of GP3, two and three aa
12 substitutions were found, respectively, whilst the non-neutralizing AR II contained two
13 mutations (Fig. 2b). The non-antigenic part of the protein contained five aa substitutions.

14 Four aa substitutions were found in the neutralizing epitope AR I of GP4 [19, 21],
15 while three mutations were observed in the non-immunogenic part of the protein (Fig. 2c).

16 In the neutralizing epitope of Type I PRRSV GP5 [22], one aa substitution was found.
17 AR I, the main epitope targeted by neutralizing antibodies in Type II strains [10], but non-
18 neutralizing epitope in the case of Type I PRRSV [19, 23], demonstrated a single aa
19 substitution. The other non-neutralizing epitopes of GP5, AR II and AR IV contain no aa
20 mutations. The non-antigenic region of the protein contained four aa substitutions (Fig. 2d). It
21 is striking that a disproportionally large number of the aa changes in ORF2-4 occur in known
22 B cell epitopes which suggests a strong immunological pressure in these regions.

23 The GP5 of isolate 9625/2012 contained three putative N-glycosylation sites at aa 37,
24 46 and 53. That of PRRSV Amervac MLV also contained three at 35, 46 and 53, while GP5
25 of Olot/1991 had only two putative N-glycosylation sites at aa 46 and 53.

26 Both PRRSV genotypes change at a rate of 0.5–1% per year in the field [24]. The 96%
27 similarity observed between 9625/2012 and Olot/1991/Amervac MLV may equate to 4–8
28 years of changing in field. Since 2004, strains with 98–99% similarity to the vaccine strain
29 have been identified in herds vaccinated with Amervac MLV [13, Bálint, personal data].
30 However, PRRSV 9625/2012 had higher genetic distance from the vaccine strain, and
31 occurred in a fattener farm that has never been vaccinated against PRRS. Yet the most
32 plausible explanation of the origin of PRRSV 9625/2012 is that it descended from Amervac
33 MLV or an Olot/1991-like, unidentified strain between 2004 and 2008, and it
34 circulated/evolved without being identified in Hungary until its appearance in 2012. Another
35 explanation could be that it was newly introduced to Hungary in 2012 as a new PRRSV
36 variant from an unidentified source.

37 Analysis of the putative amino acid sequence revealed the presence of relatively high
38 aa differences in Nsp1 and Nsp2 between 9625/2012 and related viruses. This phenomenon
39 may correspond to the fact that these proteins are involved in the blockage of the type I IFN
40 synthesis and signalling pathway [25]. Furthermore, nsp2 is the viral protein containing the
41 highest frequency in B cell epitopes [26]. The amino acid sequence variability in this protein
42 is high both within and between genotypes [27], and changes including deletions in these
43 parts of the genome might have an influence on the pathogenicity of the strains [10].

44 The two aa substitutions in the neutralizing epitopes and the three aa differences in the
45 non-neutralizing ARs, versus the three aa substitutions in the non-antigenic part of the GP2
46 protein suggest the role of selective immune pressure in the development of this strain. Those
47 variants that show bigger differences on the antigenic regions compared to the original strains
48 might have the ability to avoid or decrease the efficacy of neutralizing antibody attachment.
49 Similar tendencies have already been identified in PRRSV circulating in Hungary [13]. The
50 two aa substitutions right upstream of AR II suggest that this region might be extended N-

1 terminally, considering that its terminal border was mapped originally with a precision of
2 about two amino acids [9].

3 It has been long suspected that an ‘epitope site’ covering ARs GP3-I and GP3-II is
4 involved in functional interactions with the host cell [9, 28] but it was only recently proven
5 that antibodies against AR I have neutralizing capacity [19]. The three aa substitutions in AR
6 I and AR II, as well as the three found in the neutralizing epitope of AR VIII, may also reflect
7 immunogenic pressure.

8 In GP4, a neutralizing epitope is present in Type I PRRSV from aa 57 to 68 [21]
9 within AR I [19]. The three aa substitutions found within this sequence confirm that this
10 region is under antibody-mediated pressure *in vitro* and *in vivo* [29]. Whether these
11 substitutions contribute to the generation of an escape mutant that is not cross-neutralized
12 with PRRSV Amervac MLV or Olot/1991 is still unknown.

13 GP5 has been considered to be the main target for virus neutralizing antibodies in
14 North American PRRSV strains [10]. A neutralizing epitope has been identified at positions
15 37–45 [10], but this epitope proved to be non-neutralizing in the case of Type I PRRSV [19,
16 23]. The neutralizing epitope in Type I GP5 is located upstream of this epitope from residues
17 29 to 35 [22]. The three amino-acid substitutions present from aa 36–38 spanning the two
18 aforementioned epitopes may suggest a role of selective immunological pressure in the
19 sequence change.

20 A plausible explanation for the severe clinical signs and pathological lesions
21 observed during the outbreak could be the presence of a concurrent *Mycoplasma*
22 *hyopneumoniae* infection. Previous studies have shown an increase in the severity of the
23 pneumonia induced by dual, compared to single infection either with *Mycoplasma*
24 *hyopneumoniae* and PRRSV [30]. Moreover, increased production of proinflammatory
25 cytokines have been observed following dual inoculation with these pathogens when
26 compared to single infections [31].

27 **Acknowledgements**

28 This paper was supported by the János Bolyai Research Scholarship of the Hungarian
29 Academy of Sciences and by the OTKA fund (OTKA K-108607). We would like to thank
30 Amelia Sidwell for her grammatical suggestions.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Meulenber JJ, Hulst MM, de Meijer EJ, Moonen PL, den Besten A, de Kluyver EP, Wensvoort G, Moormann RJ (1993) Lelystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and EAV. *Virology* 192:62–72
2. Shi M, Lam TT, Hon CC, Murtaugh MP, Davies PR, Hui RK, Li J, Wong LT, Yip CW, Jiang JW, Leung FC (2010) Phylogeny-based evolutionary, demographical, and geographical dissection of North American type 2 porcine reproductive and respiratory syndrome viruses. *J Virol* 84:8700–8711
3. Stadejek T, Oleksiewicz MB, Potapchuk D, Podgórska K (2006) Porcine reproductive and respiratory syndrome virus strains of exceptional diversity in eastern Europe support the definition of new genetic subtypes. *J Gen Virol* 87:1835–1841
4. Tian K, Yu X, Zhao T, Feng Y, Cao Z, Wang C, Hu Y, Chen X, Hu D, Tian X et al (2007) Emergence of Fatal PRRSV Variants: Unparalleled Outbreaks of Atypical PRRS in China and Molecular Dissection of the Unique Hallmark. *PLoS ONE* 2:e526
5. Karniychuk UU, Geldhof M, Vanhee M, van Doorselaere J, Saveleva TA, Nauwynck HJ (2010) Pathogenesis and antigenic characterization of a new East European subtype 3 porcine reproductive and respiratory syndrome virus isolate. *BMC Vet Res* 6:30
6. Morgan SB, Graham SP, Salguero FJ, Sánchez Cordón PJ, Mokhtar H, Rebel JM, Weesendorp E, Bodman-Smith KB, Steinbach F, Frossard JP (2013) Increased pathogenicity of European porcine reproductive and respiratory syndrome virus is associated with enhanced adaptive responses and viral clearance. *Vet Microbiol* 163:13–22
7. Beura LK, Subramaniam S, Vu HL, Kwon B, Pattnaik AK, Osorio FA (2012) Identification of amino acid residues important for anti-IFN activity of porcine reproductive and respiratory syndrome virus non-structural protein 1. *Virology* 433:431–439
8. Subramaniam S, Beura LK, Kwon B, Pattnaik AK, Osorio FA (2012) Amino acid residues in the non-structural protein 1 of porcine reproductive and respiratory syndrome virus involved in down-regulation of TNF- α expression in vitro and attenuation in vivo. *Virology* 432:241–249
9. Oleksiewicz MB, Bøtner A, Normann P (2002) Porcine B-cells recognize epitopes that are conserved between the structural proteins of American- and European-type porcine reproductive and respiratory syndrome virus. *J Gen Virol* 83:1407–1418
10. Ostrowski M, Galeota JA, Jar AM, Platt KB, Osorio FA, Lopez OJ (2002) Identification of neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain. *J Virol* 76:4241–4250
11. Díaz I, Pujols J, Ganges L, Gimeno M, Darwich L, Domingo M, Mateu E (2009) In silico prediction and ex vivo evaluation of potential T-cell epitopes in glycoproteins 4 and 5 and nucleocapsid protein of genotype-I (European) of porcine reproductive and respiratory syndrome virus. *Vaccine* 27:5603–5611
12. Balka G, Hornyák A, Bálint A, Benyeda Z, Rusvai M (2009) Development of a one-step real-time quantitative PCR assay based on primer-probe energy transfer for the detection of porcine reproductive and respiratory syndrome virus. *J Virol Meth* 158:41–45
13. Balka G, Hornyák A, Bálint A, Kiss I, Kecskeméti S, Bakonyi T, Rusvai M (2008) Genetic diversity of porcine reproductive and respiratory syndrome virus strains circulating in Hungarian swine herds. *Vet Microbiol* 127:128–135

14. Manual of diagnostic tests and vaccines for terrestrial animals 2013. Office International des Epizooties (Paris), <http://www.oie.int/international-standard-setting/terrestrial-manual/access-online/>
15. Stemke GW, Phan R, Young TF, Ross RF (1994) Differentiation of *Mycoplasma hyopneumoniae*, *M flocculare*, and *M hyorhinis* on the basis of amplification of a 16S rRNA gene sequence. *Am J Vet Res* 55:81–84
16. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol* 28:2731–2739
17. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC (1999) Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. *J Virol* 73:152–160
18. Gupta R, Brunak S (2002) Prediction of N-glycosylation sites in human proteins. *Pacific Symposium on Biocomputing* 7:310–322
19. Vanhee M, Van Breedam W, Costers S, Geldhof M, Noppe Y, Nauwynck H. (2011) Characterization of antigenic regions in the porcine reproductive and respiratory syndrome virus by the use of peptide-specific serum antibodies. *Vaccine* 29:4794–4804
20. Oleksiewicz MB, Bøtner A, Toft P, Grubbe T, Nielsen J, Kamstrup S, Storgaard T (2000) Emergence of porcine reproductive and respiratory syndrome virus deletion mutants: correlation with the porcine antibody response to a hypervariable site in the ORF 3 structural glycoprotein. *Virology* 267:135–140
21. Meulenbergh JJ, van Nieuwstadt AP, van Essen-Zandbergen A, Langeveld JP (1997) Posttranslational processing and identification of a neutralization domain of the GP4 protein encoded by ORF4 of the Lelystad Virus. *J Virol* 71:6061–6070.
22. Wissink EH, van Wijk HA, Kroese MV, Weiland E, Meulenbergh JJ, Rottier PJ, van Rijn PA (2003) The major envelope protein, GP5, of a European porcine reproductive and respiratory syndrome virus contains a neutralization epitope in its N-terminal ectodomain. *J Gen Virol* 84:1535–1543
23. Van Breedam W, Costers S, Vanhee M, Gagnon CA, Rodríguez-Gómez IM, Geldhof M, Verbeeck M, Van Doorselaere J, Karniyuchuk U, Nauwynck HJ (2011) Porcine reproductive and respiratory syndrome virus (PRRSV)-specific mAbs: supporting diagnostics and providing new insights into the antigenic properties of the virus. *Vet Immunol Immunopathol* 141:246–257
24. Prieto C, Vázquez A, Núñez JI, Alvarez E, Simarro I, Castro JM (2009) Influence of time on the genetic heterogeneity of Spanish porcine reproductive and respiratory syndrome virus isolates. *Vet J* 180:363–370 (2009)
25. Chen Z, Lawson S, Sun Z, Zhou X, Guan X, Christopher-Hennings J, Nelson EA, Fang Y (2010) Identification of two auto-cleavage products of nonstructural protein 1 (nsp1) in porcine reproductive and respiratory syndrome virus infected cells: nsp1 function as interferon antagonist. *Virology* 398:87–97
26. Yan Y, Guo X, Ge X, Chen Y, Cha Z, Yang H (2007) Monoclonal antibody and porcine antisera recognized B-cell epitopes of Nsp2 protein of a Chinese strain of porcine reproductive and respiratory syndrome virus. *Virus Res* 126:207–215
27. Gauger PC, Faaberg KS, Guo B, Kappes MA, Opriessnig T (2012) Genetic and phenotypic characterization of a 2006 United States porcine reproductive and respiratory virus isolate associated with high morbidity and mortality in the field. *Virus Res* 163:98–107
28. Cancel-Tirado SM, Evans RB, Yoon KJ (2004) Monoclonal antibody analysis of porcine reproductive and respiratory syndrome virus epitopes associated with antibody-

dependent enhancement and neutralization of virus infection. *Vet Immunol Immunopathol* 102:249–262

29. Costers S, Vanhee M, Van Breedam W, Van Doorselaere J, Geldhof M, Nauwynck HJ (2010) GP4-specific neutralizing antibodies might be a driving force in PRRSV evolution. *Virus Res* 154:104–113
30. E Thacker EL, Halbur PG, Ross RF, Thanawongnuwech R, Thacker BJ (1999) *Mycoplasma hyopneumoniae* potentiation of porcine reproductive and respiratory syndrome virus-induced pneumonia. *Microbiol* 37:620–627
31. R. Thanawongnuwech R, Thacker B, Halbur P, Thacker EL (2004) Increased production of proinflammatory cytokines following infection with porcine reproductive and respiratory syndrome virus and *Mycoplasma hyopneumoniae*. *Clin Diagn Lab Immunol* 11: 901–908

1
2
3 **Table and Figure legends**
4
5


6 **Table 1.** Oligonucleotide primers used for RT-PCR amplification of PRRSV 9625/2012.
7

8 **Figure 1.** Phylogenetic analysis of the ORF5 coding region of PRRSV 9625/2012 using the
9 neighbour-joining method and adding VR-2332 Type 2 reference strain as outgroup. The
10 topology of the tree was confirmed by 1000 bootstrapping steps.
11

12
13 **Figure 2.** Alignment of a, ORF2; b, ORF3; c, ORF4 and d, ORF5. Antigenic regions are
14 shaded. Underlined sequences represent neutralizing epitopes.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure

[Click here to download Figure: fig1.pdf](#)



0.05

c,

9625/2012 : MAAAILFLLVGAQYLMVSEAFACKPCFSTHLSDIKTNNTAAAGFLVLQDINCLRPHGVPTAQETLSIRKPSQCREAVGIPQYITITANVTDESYLYNADL 100
AMERVAC :A.....M.....S.....I.FG.....
OLOT/1991 :A.....M.....S.....I.FG.....

9625/2012 : LMLSACLFYASEMSEKGFVKVIFGNVSGVVSACVNFDTDYVAHVVIQHTQQHHLAIDHIRLLHFLTPSTMRWATTIACLFALLAI 180
AMERVAC :V.....
OLOT/1991 :V.....

d,

9625/2012 : MRCSHKLGRFLTLHSCFWWLFLLCTGLSWSFVDGSDNSSTYQYIYNLTICELNGTDWLSSHFDWAVETFLVLPVATHILSLGFLTTSHFFDALGLGAVST 100
AMERVAC :E...P.....N.S.....E..P.....
OLOT/1991 :E...P.....NGB.....E..P.....

9625/2012 : TGFIGGRYVLSSVYGACAFaalVCFVIRAAKNCMACRYARTRFTNFIVDDRGRHRWKSPIVVEKLGKAEVGGDLVTIKHVVLEGVKAOPLTRTSAEQWEA 200
AMERVAC : ...V.....V.....V.....
OLOT/1991 : ...V.....V.....V.....

Table 1. Oligonucleotide primers used for RT-PCR amplification of PRRSV 9625/2012

Primer	Sequence	Position
PR_EU_15F	ATTCCCCTACATACACGACAC	15-36
PR_AVAC_2477F	CTCGGACTCCATGAAAGGAA	2477-2496
PR_EU_4719F	CCATGGTGTTCAAATCCTTTTT	4719-4740
PR_AVAC_9300F	TGTGGGAGAACTGAAAAGTCA	9300-9321
PR_AVAC_11818F	TAAAATTAGCCAGCTGTTCGTG	11818-11839
PR_AVAC_2902R	ATGATAGAGCTGGATTCGGAAA	2902-2881
PR_AVAC_5337R	CGGTGTTAAGGCAGGGTTTATG	5337-5316
PR_AVAC_9859R	CATAGTCTGATGGGTGGGTGTA	9859-9838
PR_AVAC_12552R	TTGATGGTTAGCTCGAATGATG	12552-12531
Pr15047R	T(24)AATTTTCGGTCACATGGTTCCTGCCTG	15098-15073